Indegene, a leading provider of clinical, commercial and marketing solutions to global pharmaceutical and healthcare organizations, has launched TrialPedia 2.0, its flagship clinical trial analytics and benchmarking platform. This enhanced version has analytics and benchmarking algorithms spanning over 200,000 trials across 200 indications, making it the most comprehensive and effective clinical trial analysis platform in the marketplace.

Today's Research and Development (R&D), Clinical, Medical Affairs, Health Outcomes, and Business Development and Licensing divisions face dramatic challenges in designing trial programmes, formulating clinical development strategies, and forecasting the future 'claim space' in order to benchmark and maximize the value of their pipeline. Operational challenges as well as, time and cost delays in clinical trials can have a significant impact on revenues and future profitability. TrialPedia 2.0 further enhances the quality, speed, and effectiveness of the clinical development and strategic planning process for global pharmaceutical, device, and biotech organizations. This new release includes improved granular search, advanced sub-disease classification, expanded trial and indication coverage, increased geographical scope, and disease-specific interventions.

The platform makes the identification of gaps, and development of appropriate benchmarks for the clinical development process more efficient. This is particularly important, given the increase in regulatory thresholds and challenges surrounding adverse events. It helps minimize this by identifying industry best practices vis-à-vis safety and efficacy, thereby avoiding costly late-stage delays and failures. The new release marks advanced analytics and benchmarking tools to provide for an aggressive strategy of label leadership across sub-indications, biomarkers, and launch preparations.

Indegene is a leading provider of clinical, commercial and marketing solutions to global pharmaceutical and healthcare organizations.